Last reviewed · How we verify
Eliglustat, CD30 target immunotherapy
Eliglustat, CD30 target immunotherapy is a Small molecule drug developed by Chinese PLA General Hospital. It is currently in Phase 1 development.
At a glance
| Generic name | Eliglustat, CD30 target immunotherapy |
|---|---|
| Sponsor | Chinese PLA General Hospital |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Eliglustat, CD30 target immunotherapy CI brief — competitive landscape report
- Eliglustat, CD30 target immunotherapy updates RSS · CI watch RSS
- Chinese PLA General Hospital portfolio CI
Frequently asked questions about Eliglustat, CD30 target immunotherapy
What is Eliglustat, CD30 target immunotherapy?
Eliglustat, CD30 target immunotherapy is a Small molecule drug developed by Chinese PLA General Hospital.
Who makes Eliglustat, CD30 target immunotherapy?
Eliglustat, CD30 target immunotherapy is developed by Chinese PLA General Hospital (see full Chinese PLA General Hospital pipeline at /company/chinese-pla-general-hospital).
What development phase is Eliglustat, CD30 target immunotherapy in?
Eliglustat, CD30 target immunotherapy is in Phase 1.